Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The PI3K/mTOR Inhibitor Ompalisib Suppresses Nonhomologous End Joining and Sensitizes Cancer Cells to Radio- and Chemotherapy

30 Jul 2021

Abstract excerpt

Abstract As the predominant pathway for the repair of DNA double-strand breaks (DSB), non-homologous end joining (NHEJ) attenuates the efficacy of cancer treatment which relies on the introduction of DSBs, such as radiotherapy and genotoxic drugs. Identifying novel NHEJ inhibitors is of great importance for improving the therapeutic efficiency of radio- or chemotherapy. Here we miniaturized our recently developed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34330845
DOI: 10.1158/1541-7786.mcr-21-0301

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The PI3K/mTOR Inhibitor Ompalisib Suppresses Nonhomologous End Joining and Sensitizes Cancer Cells to Radio- and ChemotherapyPMID 34330845Read ↗

DNA damage response signaling pathways and targets for radiotherapy sensitization in cancerSemantic proximity Read ↗

Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the PromisingSemantic proximity Read ↗

Recent Advances in the Development of Non-PIKKs Targeting Small Molecule Inhibitors of DNA Double-Strand Break RepairSemantic proximity Read ↗

Advancing cancer therapy: new frontiers in targeting DNA damage responseSemantic proximity Read ↗

Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand BreaksSemantic proximity Read ↗

Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair InhibitorsSemantic proximity Read ↗

Targeting DNA Double-Strand Break (DSB) Repair to Counteract Tumor Radio-resistanceSemantic proximity Read ↗

Molecular targets that sensitize cancer to radiation killing: From the bench to the bedsideSemantic proximity Read ↗

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activitySemantic proximity Read ↗

VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cellsSemantic proximity Read ↗

Triple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escapeSemantic proximity Read ↗

Ionizing Radiation-Induced DNA Damage, Response, and RepairSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.